Hosted on MSN1mon
Tris Pharma reports positive data from Phase III acute pain therapy trial
Cebranopadol's dual-NMR agonism could help manage pain by balancing analgesic efficacy and safety. The company anticipates sharing additional trial outcomes in the first quarter of this year.
Nature14d
Mechanism of action articles from across Nature Portfolio
PPARγ nuclear receptor ligand activities can span agonism to inverse agonism. Here, the authors use NMR to show how chemical changes within a ligand series shift the receptor’s dynamic ...
Business Wire1mon
Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of ...
“Our team was impressed by the magnitude of analgesia seen, suggesting that cebranopadol’s novel mechanism of dual-NMR agonism has the potential to be as effective as opioids in the post ...
ascopubs.org24d
GLP1R expression in prostate cancer patients and effects of GLP1R agonism on prostate cancer cells.
CTC and AR-V7 analysis in the ECOG-ACRIN 8153 (CHAARTED2) randomized trial: Abiraterone (Abi) with or without cabazitaxel (Abi-Cabazi) in extensive mCRPC following docetaxel. This is an ASCO Meeting ...